Acute Lymphocytic Leukemia

Size: px
Start display at page:

Download "Acute Lymphocytic Leukemia"

Transcription

1 Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin (Blenoxane ) Bortezomib (Velcade ) Bosutinib (Bosulif ) Busulfan (Myleran ) Carmustine (BCNU, BiCNU) Chlorambucil (Leukeran ) Cladribine (2-CDA, Leustatin ) Cyclophosphamide (Cytoxan, Neosar ) Cytarabine (Cytosar-U, Ara-C) Dacarbazine (DTIC) Dactinomycin (Cosmegen ) Dasatinib (Sprycelt ) Daunorubicin (Cerubidine, daunomycin) Dexamethasone (decadron) Epirubicin (Ellence, Pharmorubicin ) Etoposide (VePesid, VP-16) Fludarabine (Fludara ) Gemtuzumab ozogamacin (Myelotarg ) Hydroxyurea (Hydrea ) Idarubicin (Idamycin ) Ifosfamide (IFEX ) Imatinib (Gleevec, STI-571) Interferon Alpha (Intron-A, Roferon-A ) L-Asparaginase (Elspar ) Lenalidomide (Revlimid ) Mechlorethamine (Mustargen, Nitrogen Mustard) Melphalan (Alkeran, L-PAM) Methotrexate (MTX) Methylprednisolone (Solumedrol, Medrol) Mitoxantrone (Novantrone ) Nelarabine (Arranon ) Nilotinib (Tasigna ) PEG-Asparaginase Prednisone (used as chemotherapy, doses > 20mg) Procarbazine (Mutalane ) Rituximab (Rituxan ) Teniposide (Vumon ) Thalidomide (Thalomid ) Tretinoin (Vesanoid, All-trans retinoic acid, ATRA) Vinblastine (Velban ) Vincristine (Oncovin ) Vinorelbine (Navelbine ) for metastasis to the bone for metastasis to the brain or spinal Total Body Irradiation

2 Acute Myeloid Leukemia Splenectomy (Removal of Spleen) Arsenic Trioxide (Trisenox ) Azacitidine (Vidaza ) Bortezomib (Velcade ) Busulfan (Myleran ) Chlorambucil (Leukeran ) Cladribine (2-CDA, Leustatin ) Cyclophosphamide (Cytoxan, Neosar ) Cytarabine (Cytosar-U, Ara-C) Daunorubicin (Cerubidine, daunomycin) Decitabine (Dacogen ) Epirubicin (Ellence, Pharmorubicin ) Etoposide (VePesid, VP-16) Fludarabine (Fludara ) Gemtuzumab ozogamacin (Myelotarg ) Hydroxyurea (Hydrea ) Idarubicin (Idamycin ) Ifosfamide (IFEX ) Lenalidomide (Revlimid ) Melphalan (Alkeran, L-PAM) Mitoxantrone (Novantrone ) Teniposide (Vumon ) Tretinoin (Vesanoid, All-trans retinoic acid, ATRA) for metastasis to the bone for metastasis to the brain or spinal Total Body Irradiation

3 Anal Cancer Permanent Colostomy or Ileostomy Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for Rectal or Anal Cancer to Remove Female Reproductive Organs (hysterectomy, oopherectomy) Bevacizumab (Avastin ) Capecitabine (Xeloda ) Cetuximab (Erbitux ) Fluorouracil (Adrucil, 5-FU) Irinotecan (Camptosar, CPT -11) Mitomycin (Mitomycin C, Mutamycin) Oxaliplatin (Eloxatin ) Panitumumab (Vectibix ) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung Treatment for colon, rectal or anal cancer

4 Appendiceal Cancer Removal of a Section of the Bowel for Appendiceal Cancer (Removal of appendix / Appendectomy) Bevacizumab (Avastin ) Capecitabine (Xeloda ) Cetuximab (Erbitux ) Fluorouracil (Adrucil, 5-FU) Irinotecan (Camptosar, CPT -11) Oxaliplatin (Eloxatin ) for metastasis to the bone for metastasis to the lung for metastasis to the lymph nodes to the Liver Treatment for Cancer of the Appendix

5 Bladder Cancer Permanent Colostomy or Ileostomy Removal of the Bladder (cystectomy, bladder resection) Removal of the Prostate (Prostatectomy) Treatment for bladder cancer to Remove Female Reproductive Organs (hysterectomy, oopherectomy) (Given IV) Carboplatin (Paraplatin ) Docetaxel (Taxotere ) Fluorouracil (Adrucil, 5-FU) Methotrexate (MTX) Mitomycin (Mitomycin C, Mutamycin) Paclitaxel (Taxol ) Pemetrexed (Alimta ) Vinblastine (Velban ) Therapy Given into the Bladder (Intravesicular) Bacillus Calmette-Guérin (BCG, TICE ) Doxorubicin (Adriamycin, Rubex, Doxil ) Epirubicin (Ellence, Pharmorubicin ) Interferon Alpha (Intron-A, Roferon-A ) Mitomycin (Mitomycin C, Mutamycin) Thiotepa (Thioplex )

6 Brain Cancer Involving the Brain or Spinal Cord Prophylactic Cranial Irradiation (PCI) Treatment for brain and spinal tumors Bevacizumab (Avastin ) Carboplatin (Paraplatin ) Carmustine (BCNU, BiCNU) Dexamethasone (decadron) Etoposide (VePesid, VP-16) Interferon Alpha (Intron-A, Roferon-A ) Irinotecan (Camptosar, CPT -11) Lomustine (CCNU, CeeNU ) Pemetrexed (Alimta ) Prednisone (used as chemotherapy, doses > 20mg) Procarbazine (Mutalane ) Temozolomide (Temodar ) Topotecan (Hycamtin ) Vincristine (Oncovin )

7 Breast Cancer Lumpectomy Lymph nodes taken from above the waist Mastectomy Sentinel Node Biopsy Abraxane Ado-trastuzumab emtansine (Kadcyla ) Bevacizumab (Avastin ) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Cyclophosphamide (Cytoxan, Neosar ) Docetaxel (Taxotere ) Doxil Liposome (Doxil ) Epirubicin (Ellence, Pharmorubicin ) Eribulin Mesylate (Halaven ) Etoposide (VePesid, VP-16) Everolimus (Afinitor ) Fluorouracil (Adrucil, 5-FU) Ixabepilone (Ixempra ) Lapatinib (Tykerb ) Methotrexate (MTX) Paclitaxel (Taxol ) Pertuzumab (Perjeta ) Trastuzumab (Herceptin ) Vinorelbine (Navelbine ) Treatment for breast cancer after lumpectomy Treatment for breast cancer after mastectomy Treatment for Breast Cancer Using Partial Breast Irradiation (PBI, Mammosite ) for metastases to the liver for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes to the skin (metastases or primary cancer) Hormone Therapy Anastrozole (Arimidex ) Exemestane (Aromasin ) Fulvestrant (Faslodex ) Letrozole (Femara ) Leuprolide (Lupron, Eligard, Viadur) Megestrol acetate (Megace ) Raloxifene (Evista ) Tamoxifen (Nolvadex ) Toremifene (Fareston )

8 Cervical Cancer cervical, ovarian, fallopian or vulvar/ vaginal cancers) Lymph nodes taken from below the waist Permanent Colostomy or Ileostomy Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for ovarian, primary peritoneal, fallopian tube, endometrial/uterine and cervical cancers Abraxane Bevacizumab (Avastin ) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Docetaxel (Taxotere ) Fluorouracil (Adrucil, 5-FU) Ifosfamide (IFEX ) Irinotecan (Camptosar, CPT -11) Mitomycin (Mitomycin C, Mutamycin) Paclitaxel (Taxol ) Pemetrexed (Alimta ) Topotecan (Hycamtin ) Vinorelbine (Navelbine ) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for female reproductive tract ( for endometrial, uterine,

9 Chronic Lymphocytic Leukemia Total Body Irradiation Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Bendamustine (Treanda ) Busulfan (Myleran ) Chlorambucil (Leukeran ) Cladribine (2-CDA, Leustatin ) Cyclophosphamide (Cytoxan, Neosar ) Daunorubicin (Cerubidine, daunomycin) Dexamethasone (decadron) Epirubicin (Ellence, Pharmorubicin ) Fludarabine (Fludara ) Hydroxyurea (Hydrea ) Idarubicin (Idamycin ) L-Asparaginase (Elspar ) Lenalidomide (Revlimid ) Melphalan (Alkeran, L-PAM) Mitoxantrone (Novantrone ) Obinutuzumab (Gazyva ) Ofatumumab (Arzerra ) Prednisone (used as chemotherapy, doses > 20mg) Rituximab (Rituxan ) Vincristine (Oncovin ) for metastasis to the bone for metastasis to the brain or spinal Treatment for Hodgkin's disease ("Mantle Field") Treatment for lymphoma ( to chest/mediastinum/neck) Treatment for lymphoma ( to groin/abdomen)

10 Chronic Myelogenous Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Bosutinib (Bosulif ) Busulfan (Myleran ) Chlorambucil (Leukeran ) Cyclophosphamide (Cytoxan, Neosar ) Cytarabine (Cytosar-U, Ara-C) Dasatinib (Sprycelt ) Dexamethasone (decadron) Etoposide (VePesid, VP-16) Hydroxyurea (Hydrea ) Idarubicin (Idamycin ) Ifosfamide (IFEX ) Imatinib (Gleevec, STI-571) Interferon Alpha (Intron-A, Roferon-A ) Melphalan (Alkeran, L-PAM) Methotrexate (MTX) Nilotinib (Tasigna ) Omacetaxine Mepesuccinate (Synribo ) Thiotepa (Thioplex ) Vincristine (Oncovin ) for metastasis to the brain or spinal Total Body Irradiation

11 Colon Cancer Lung Resection Lymph nodes taken from below the waist Permanent Colostomy or Ileostomy Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for Rectal or Anal Cancer to Remove Female Reproductive Organs (hysterectomy, oopherectomy) Bevacizumab (Avastin ) Capecitabine (Xeloda ) for metastases to the liver for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung Treatment for colon, rectal or anal cancer Cetuximab (Erbitux ) Fluorouracil (Adrucil, 5-FU) Irinotecan (Camptosar, CPT -11) Mitomycin (Mitomycin C, Mutamycin) Oxaliplatin (Eloxatin ) Panitumumab (Vectibix ) Regorafenib (Stivarga ) Ziv-Aflibercept (Zaltrap )

12 Endometrial Cancer Lymph nodes taken from below the waist Permanent Colostomy or Ileostomy Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for ovarian, primary peritoneal, fallopian tube, endometrial/uterine and cervical cancers for vaginal and vulvar cancers Bevacizumab (Avastin ) Carboplatin (Paraplatin ) Dacarbazine (DTIC) Docetaxel (Taxotere ) Doxil Liposome (Doxil ) Epirubicin (Ellence, Pharmorubicin ) Ifosfamide (IFEX ) Paclitaxel (Taxol ) Pazopanib (Votrient ) Temozolomide (Temodar ) Temsirolimus (Torisel ) Topotecan (Hycamtin ) Vinorelbine (Navelbine ) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for female reproductive tract ( for endometrial, uterine, cervical, ovarian, fallopian or vulvar/ vaginal cancers) Hormone Therapy Anastrozole (Arimidex ) Exemestane (Aromasin ) Fulvestrant (Faslodex ) Goserelin (Zoladex ) Letrozole (Femara ) Leuprolide (Lupron, Eligard, Viadur) Megestrol acetate (Megace ) Tamoxifen (Nolvadex )

13 Esophageal Cancer Lymph nodes taken from above the waist Other Surgeries Not Listed Removal of the Esophagus (esophagectomy) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Docetaxel (Taxotere ) Epirubicin (Ellence, Pharmorubicin ) Erlotinib (Tarceva ) Etoposide (VePesid, VP-16) Fluorouracil (Adrucil, 5-FU) Irinotecan (Camptosar, CPT -11) Mitomycin (Mitomycin C, Mutamycin) Oxaliplatin (Eloxatin ) Paclitaxel (Taxol ) Trastuzumab (Herceptin ) for metastasis to the bone for metastasis to the lung for metastasis to the lymph nodes to the Liver Treatment for esophageal cancer

14 Fallopian Tube Cancer Lymph nodes taken from below the waist Other Surgeries Not Listed Permanent Colostomy or Ileostomy Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for ovarian, primary peritoneal, fallopian tube, endometrial/uterine and cervical cancers for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for female reproductive tract ( for endometrial, uterine, cervical, ovarian, fallopian or vulvar/ vaginal cancers) Abraxane Altretamine (Hexalen, HMM) Bevacizumab (Avastin ) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Cyclophosphamide (Cytoxan, Neosar ) Docetaxel (Taxotere ) Doxil Liposome (Doxil ) Etoposide (VePesid, VP-16) Ifosfamide (IFEX ) Irinotecan (Camptosar, CPT -11) Melphalan (Alkeran, L-PAM) Oxaliplatin (Eloxatin ) Paclitaxel (Taxol ) Pemetrexed (Alimta ) Topotecan (Hycamtin ) Vinorelbine (Navelbine ) Hormone Therapy Anastrozole (Arimidex ) Letrozole (Femara ) Leuprolide (Lupron, Eligard, Viadur) Megestrol acetate (Megace ) Tamoxifen (Nolvadex )

15 Gall Bladder / Cholangiocarcinoma Liver Resection Removal of a Section of the Bowel for Gall Bladder Cancer (gall bladder removal / cholecystectomy) Docetaxel (Taxotere ) Erlotinib (Tarceva ) Fluorouracil (Adrucil, 5-FU) Oxaliplatin (Eloxatin ) for metastasis to the bone for metastasis to the lung for metastasis to the lymph nodes to the Liver Treatment for biliary cancer (radiation to gallbladder, pancreas, or ampulla of vader)

16 Head & Neck: Tongue, Lip, Oropharynx, Nasopharynx Head and Neck Surgeries Laryngectomy Lymph nodes taken from above the waist Removal of the Thyroid (thyroidectomy) Bleomycin (Blenoxane ) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Cetuximab (Erbitux ) Docetaxel (Taxotere ) Epirubicin (Ellence, Pharmorubicin ) Fluorouracil (Adrucil, 5-FU) Hydroxyurea (Hydrea ) Ifosfamide (IFEX ) Methotrexate (MTX) Paclitaxel (Taxol ) Vinorelbine (Navelbine ) for metastasis to the bone for metastasis to the lung for metastasis to the lymph nodes to the skin (metastases or primary cancer) Treatment for head and neck cancers

17 Hodgkin's Disease Lymph nodes taken from above & below the waist Lymph nodes taken from above the waist Lymph nodes taken from below the waist Splenectomy (Removal of Spleen) Uncertain if lymph nodes were above or below the waist for metastasis to the brain or spinal to the Spleen Treatment for Hodgkin's disease ("Mantle Field") Treatment for lymphoma ( to groin/abdomen) Total Body Irradiation Bendamustine (Treanda ) Bleomycin (Blenoxane ) Brentuximab Vedotin (Adcetris, SGN-35) Carmustine (BCNU, BiCNU) Cyclophosphamide (Cytoxan, Neosar ) Cytarabine (Cytosar-U, Ara-C) Dacarbazine (DTIC) Dexamethasone (decadron) Doxil Liposome (Doxil ) Etoposide (VePesid, VP-16) Ifosfamide (IFEX ) Lenalidomide (Revlimid ) Mechlorethamine (Mustargen, Nitrogen Mustard) Melphalan (Alkeran, L-PAM) Methylprednisolone (Solumedrol, Medrol) Mitoxantrone (Novantrone ) Prednisone (used as chemotherapy, doses > 20mg) Procarbazine (Mutalane ) Rituximab (Rituxan ) Teniposide (Vumon ) Vinblastine (Velban ) Vincristine (Oncovin )

18 Kidney Cancer Removal of the Kidney (Full or Partial Nephrectomy) Axitinib (Inlyta ) Bevacizumab (Avastin ) Erlotinib (Tarceva ) Everolimus (Afinitor ) Interleukin-2 (IL-2, Aldesleukin, Proleukin ) Pazopanib (Votrient ) Sorafenib (Nexavar ) Sunitinib malate (Sutent ) Temsirolimus (Torisel ) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung to the Kidney

19 Liver Cancer Liver Resection Bevacizumab (Avastin ) Fluorouracil (Adrucil, 5-FU) Interferon Alpha (Intron-A, Roferon-A ) Oxaliplatin (Eloxatin ) Sorafenib (Nexavar ) Sunitinib malate (Sutent ) for metastasis to the lung for metastasis to the lymph nodes to the Liver

20 Lung Cancer Lung Resection Abraxane Afatinib (Gilotrif ) Bevacizumab (Avastin ) Carboplatin (Paraplatin ) Cetuximab (Erbitux ) Crizotinib (Xalkori ) Docetaxel (Taxotere ) Prophylactic Cranial Irradiation (PCI) for metastases to the liver for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lymph nodes Treatment for Lung Cancer Erlotinib (Tarceva ) Etoposide (VePesid, VP-16) Ifosfamide (IFEX ) Irinotecan (Camptosar, CPT -11) Mitomycin (Mitomycin C, Mutamycin) Paclitaxel (Taxol ) Pemetrexed (Alimta ) Topotecan (Hycamtin ) Vinblastine (Velban ) Vinorelbine (Navelbine )

21 Lymphoma Lymph nodes taken from above & below the waist Lymph nodes taken from above the waist Lymph nodes taken from below the waist Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin (Blenoxane ) Bortezomib (Velcade ) Brentuximab Vedotin (Adcetris, SGN-35) Busulfan (Myleran ) Carmustine (BCNU, BiCNU) Chlorambucil (Leukeran ) Cladribine (2-CDA, Leustatin ) Cyclophosphamide (Cytoxan, Neosar ) Cytarabine (Cytosar-U, Ara-C) Daunorubicin (Cerubidine, daunomycin) Dexamethasone (decadron) Doxil Liposome (Doxil ) Epirubicin (Ellence, Pharmorubicin ) Etoposide (VePesid, VP-16) Fludarabine (Fludara ) Gemtuzumab ozogamacin (Myelotarg ) Ibritumomab tiuxetan (Zevalin ) Ibrutinib (Imbruvica ) Ifosfamide (IFEX ) Imatinib (Gleevec, STI-571) Interferon Alpha (Intron-A, Roferon-A ) Isotretinoin (Accutane ) L-Asparaginase (Elspar ) Lenalidomide (Revlimid ) Mechlorethamine (Mustargen, Nitrogen Mustard) Melphalan (Alkeran, L-PAM) Methotrexate (MTX) Methylprednisolone (Solumedrol, Medrol) Mitoxantrone (Novantrone ) Nilotinib (Tasigna ) Obinutuzumab (Gazyva ) Ofatumumab (Arzerra ) Oxaliplatin (Eloxatin ) PEG-Asparaginase Pralatrexate (Folotyn ) Prednisone (used as chemotherapy, doses > 20mg) Procarbazine (Mutalane ) Rituximab (Rituxan ) Romidepsin (Istodax ) Teniposide (Vumon ) Tositumomab (Bexxar ) Tretinoin (Vesanoid, All-trans retinoic acid, ATRA) Vinblastine (Velban ) Vincristine (Oncovin ) Vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) for metastasis to the brain or spinal Treatment for lymphoma ( to chest/mediastinum/neck) Treatment for lymphoma ( to groin/abdomen) Total Body Irradiation

22 Melanoma for metastasis to the lymph nodes to the skin (metastases or primary cancer) Isolated Limb Perfusion (ILP) / Isolated Limb Infusion (ILI) Lymph nodes taken from above & below the waist Lymph nodes taken from above the waist Lymph nodes taken from below the waist Melanoma Excision or Moh's Sentinel Node Biopsy Abraxane Carboplatin (Paraplatin ) Carmustine (BCNU, BiCNU) Dabrafenib (Tafinlar ) Dacarbazine (DTIC) Interferon Alpha (Intron-A, Roferon-A ) Interleukin-2 (IL-2, Aldesleukin, Proleukin ) Ipilimumab (Yervoy ) Megestrol acetate (Megace ) Melphalan (Alkeran, L-PAM) Paclitaxel (Taxol ) Temozolomide (Temodar ) Trametinib (Mekinist ) Vemurafenib (Zelboraf, PLX4032) Vinblastine (Velban ) Hormone Therapy Tamoxifen (Nolvadex ) for metastases to the liver for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung

23 Mesothelioma Lung Resection for Mesothelioma Carboplatin (Paraplatin ) Docetaxel (Taxotere ) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for mesothelioma Fludarabine (Fludara ) Methotrexate (MTX) Paclitaxel (Taxol ) Pemetrexed (Alimta ) Vincristine (Oncovin ) Vinorelbine (Navelbine ) Vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA)

24 Multiple Myeloma Splenectomy (Removal of Spleen) Bendamustine (Treanda ) Bortezomib (Velcade ) Busulfan (Myleran ) Carfilzomib (Kyprolis ) for metastasis to the bone for metastasis to the brain or spinal Total Body Irradiation Cyclophosphamide (Cytoxan, Neosar ) Dexamethasone (decadron) Doxil Liposome (Doxil ) Etoposide (VePesid, VP-16) Interferon Alpha (Intron-A, Roferon-A ) Lenalidomide (Revlimid ) Melphalan (Alkeran, L-PAM) Methylprednisolone (Solumedrol, Medrol) Prednisone (used as chemotherapy, doses > 20mg) Thalidomide (Thalomid ) Vincristine (Oncovin ) Vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA)

25 Myelodysplastic Syndrome (MDS) Arsenic Trioxide (Trisenox ) Azacitidine (Vidaza ) Cyclophosphamide (Cytoxan, Neosar ) Cytarabine (Cytosar-U, Ara-C) Decitabine (Dacogen ) Epirubicin (Ellence, Pharmorubicin ) Idarubicin (Idamycin ) Isotretinoin (Accutane ) Lenalidomide (Revlimid ) Melphalan (Alkeran, L-PAM) Topotecan (Hycamtin ) Total Body Irradiation

26 Non-Melanoma Skin Cancers Lymph nodes taken from above & below the waist Lymph nodes taken from above the waist Lymph nodes taken from below the waist Melanoma Excision or Moh's Sentinel Node Biopsy Fluorouracil / 5-FU (Topical Cream) Interferon Alpha (Intron-A, Roferon-A ) Isotretinoin (Accutane ) to the skin (metastases or primary cancer)

27 Ovarian Cancer / Primary Peritoneal Cancer Lymph nodes taken from below the waist Permanent Colostomy or Ileostomy Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for female reproductive tract ( for endometrial, uterine, cervical, ovarian, fallopian or vulvar/ vaginal cancers) for ovarian, primary peritoneal, fallopian tube, endometrial/uterine and cervical cancers Abraxane Altretamine (Hexalen, HMM) Bevacizumab (Avastin ) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Cyclophosphamide (Cytoxan, Neosar ) Dactinomycin (Cosmegen ) Docetaxel (Taxotere ) Doxil Liposome (Doxil ) Etoposide (VePesid, VP-16) Ifosfamide (IFEX ) Irinotecan (Camptosar, CPT -11) Melphalan (Alkeran, L-PAM) Oxaliplatin (Eloxatin ) Paclitaxel (Taxol ) Pemetrexed (Alimta ) Topotecan (Hycamtin ) Vinblastine (Velban ) Vincristine (Oncovin ) Vinorelbine (Navelbine ) Hormone Therapy Anastrozole (Arimidex ) Letrozole (Femara ) Leuprolide (Lupron, Eligard, Viadur) Megestrol acetate (Megace ) Tamoxifen (Nolvadex )

28 Pancreatic Cancer Whipple Procedure (pancreatectomy) Abraxane Capecitabine (Xeloda ) Docetaxel (Taxotere ) Erlotinib (Tarceva ) Fluorouracil (Adrucil, 5-FU) Irinotecan (Camptosar, CPT -11) Oxaliplatin (Eloxatin ) for metastasis to the lung for metastasis to the lymph nodes to the Liver Treatment for biliary cancer (radiation to gallbladder, pancreas, or ampulla of vader)

29 Penile Cancer Lymph nodes taken from below the waist for Penile Cancer (Moh s surgery/full or partial penectomy / Removal of the penis) Bleomycin (Blenoxane ) Docetaxel (Taxotere ) Fluorouracil / 5-FU (Topical Cream) Ifosfamide (IFEX ) Methotrexate (MTX) Mitomycin (Mitomycin C, Mutamycin) Paclitaxel (Taxol ) Panitumumab (Vectibix ) for metastasis to the lymph nodes Treatment for Penile Cancer

30 Prostate Cancer Lymph nodes taken from below the waist Removal of the Prostate (Prostatectomy) Abiraterone acetate (Zytiga) Bicalutimide (Casodex ) for metastasis to the bone for metastasis to the lung for metastasis to the lymph nodes Treatment for prostate cancer Cabazitaxel (Jevtana ) Degarelix (Firmagon) Dexamethasone (decadron) Docetaxel (Taxotere ) Enzalutamide (Xtandi ) Flutamide (Eulexin ) Goserelin (Zoladex ) Leuprolide (Lupron, Eligard, Viadur) Mitoxantrone (Novantrone ) Nilutamide (Nilandron ) Prednisone (used as chemotherapy, doses > 20mg) Sipuleucel-T (Provenge ) Triptorelin (Trelstar )

31 Rectal Cancer Lung Resection Lymph nodes taken from below the waist Permanent Colostomy or Ileostomy Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for Rectal or Anal Cancer to Remove Female Reproductive Organs (hysterectomy, oopherectomy) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung Treatment for colon, rectal or anal cancer Bevacizumab (Avastin ) Capecitabine (Xeloda ) Cetuximab (Erbitux ) Fluorouracil (Adrucil, 5-FU) Irinotecan (Camptosar, CPT -11) Mitomycin (Mitomycin C, Mutamycin) Oxaliplatin (Eloxatin ) Panitumumab (Vectibix ) Regorafenib (Stivarga ) Ziv-Aflibercept (Zaltrap )

32 Sarcoma Amputation (Removal of a Limb) Isolated Limb Perfusion (ILP) / Isolated Limb Infusion (ILI) Lung Resection Removal of a Section of the Bowel to Remove the Stomach (Gastrectomy) Bevacizumab (Avastin ) Crizotinib (Xalkori ) Cyclophosphamide (Cytoxan, Neosar ) Dacarbazine (DTIC) Dactinomycin (Cosmegen ) Dasatinib (Sprycelt ) Docetaxel (Taxotere ) Doxil Liposome (Doxil ) Epirubicin (Ellence, Pharmorubicin ) Etoposide (VePesid, VP-16) Everolimus (Afinitor ) Ifosfamide (IFEX ) Imatinib (Gleevec, STI-571) Methotrexate (MTX) Nilotinib (Tasigna ) Paclitaxel (Taxol ) Pazopanib (Votrient ) Regorafenib (Stivarga ) Sorafenib (Nexavar ) Sunitinib malate (Sutent ) Temozolomide (Temodar ) Topotecan (Hycamtin ) Vinblastine (Velban ) Vincristine (Oncovin ) Vinorelbine (Navelbine ) for metastasis to the bone for metastasis to the lung for metastasis to the lymph nodes Treatment for sarcomas (chest and chest Wall) Treatment for sarcomas (retroperitoneal and abdominal) Treatment for sarcomas of the extremity (arm/leg)

33 Stomach Cancer to Remove the Stomach (Gastrectomy) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Cetuximab (Erbitux ) for metastasis to the lung for metastasis to the lymph nodes to the Liver Treatment for gastric (stomach) cancer Docetaxel (Taxotere ) Doxil Liposome (Doxil ) Epirubicin (Ellence, Pharmorubicin ) Erlotinib (Tarceva ) Etoposide (VePesid, VP-16) Fluorouracil (Adrucil, 5-FU) Irinotecan (Camptosar, CPT -11) Mitomycin (Mitomycin C, Mutamycin) Oxaliplatin (Eloxatin ) Paclitaxel (Taxol ) Ramucirumab (Cyramza ) Trastuzumab (Herceptin )

34 Testicular Cancer Removal of the Testicle(s) (Orchiectomy) Retroperitoneal Lymph Node Dissection (RPLND) for Testicular Cancer Bleomycin (Blenoxane ) Carboplatin (Paraplatin ) Cyclophosphamide (Cytoxan, Neosar ) Etoposide (VePesid, VP-16) Ifosfamide (IFEX ) Oxaliplatin (Eloxatin ) Paclitaxel (Taxol ) Vinblastine (Velban ) for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for testicular cancer

35 Thymoma or Thymic Carcinoma Lung Resection Lymph nodes taken from above the waist for Thymoma or Thymic Carcinoma Cyclophosphamide (Cytoxan, Neosar ) Etoposide (VePesid, VP-16) Fluorouracil (Adrucil, 5-FU) Ifosfamide (IFEX ) Paclitaxel (Taxol ) Pemetrexed (Alimta ) Prednisone (used as chemotherapy, doses > 20mg) Vincristine (Oncovin ) for metastasis to the lymph nodes Treatment for Thymoma or Thymic Carcinoma

36 Thyroid Cancer Removal of the Thyroid (thyroidectomy) Cabozantinib (Cometriq ) Carboplatin (Paraplatin ) Dacarbazine (DTIC) Paclitaxel (Taxol ) Pazopanib (Votrient ) Sorafenib (Nexavar ) Sunitinib malate (Sutent ) Vandetanib (Caprelsa) for metastasis to the lymph nodes Treatment for Thyroid Cancer

37 Uterine cancer Lymph nodes taken from above & below the waist Lymph nodes taken from below the waist Permanent Colostomy or Ileostomy Removal of a Section of the Bowel for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for female reproductive tract ( for endometrial, uterine, cervical, ovarian, fallopian or vulvar/ vaginal cancers) Removal of the Bladder (cystectomy, bladder resection) for ovarian, primary peritoneal, fallopian tube, endometrial/uterine and cervical cancers Bevacizumab (Avastin ) Carboplatin (Paraplatin ) Dacarbazine (DTIC) Docetaxel (Taxotere ) Doxil Liposome (Doxil ) Epirubicin (Ellence, Pharmorubicin ) Ifosfamide (IFEX ) Oxaliplatin (Eloxatin ) Paclitaxel (Taxol ) Pazopanib (Votrient ) Temozolomide (Temodar ) Temsirolimus (Torisel ) Topotecan (Hycamtin ) Vinorelbine (Navelbine ) Hormone Therapy Anastrozole (Arimidex ) Exemestane (Aromasin ) Fulvestrant (Faslodex ) Goserelin (Zoladex ) Letrozole (Femara ) Leuprolide (Lupron, Eligard, Viadur) Megestrol acetate (Megace ) Tamoxifen (Nolvadex )

38 Vaginal and Vulvar Cancers Lymph nodes taken from above & below the waist Lymph nodes taken from below the waist Removal of a Section of the Bowel Removal of the Bladder (cystectomy, bladder resection) for ovarian, primary peritoneal, fallopian tube, endometrial/uterine and cervical cancers for vaginal and vulvar cancers for metastasis to the bone for metastasis to the brain or spinal for metastasis to the lung for metastasis to the lymph nodes Treatment for female reproductive tract ( for endometrial, uterine, cervical, ovarian, fallopian or vulvar/ vaginal cancers) Bleomycin (Blenoxane ) Capecitabine (Xeloda ) Carboplatin (Paraplatin ) Erlotinib (Tarceva ) Fluorouracil (Adrucil, 5-FU) Mitomycin (Mitomycin C, Mutamycin) Paclitaxel (Taxol ) Topotecan (Hycamtin )

Chemotherapy 101 for Radiation Oncology Workers

Chemotherapy 101 for Radiation Oncology Workers Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent

More information

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy

More information

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW

More information

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years

More information

To help doctors give their patients the best possible care, the American

To help doctors give their patients the best possible care, the American Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific

More information

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607) Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally

More information

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1 drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A

More information

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

Ovarian Cancer. compendia TREATMENT OF

Ovarian Cancer. compendia TREATMENT OF drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management

More information

Introduction to Antineoplastic Prescribing

Introduction to Antineoplastic Prescribing Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand

More information

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

More information

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2

More information

ALKYLATING AGENTS (22)

ALKYLATING AGENTS (22) Serving the United States, Canada and North Central America MEMBER OF TEXAS HEALTH CARE ENTITIES A PRIVATE MEMBERSHIP MEDICAL ASSOCIATION 3105 MAIN STREET, ROWLETT, TX 75088 TEL: 214-299-9449 office@rgccusa.com

More information

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

More information

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:

More information

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or

More information

Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A

More information

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet ) Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important

More information

Bladder Cancer (Urothelial) Pathways

Bladder Cancer (Urothelial) Pathways Bladder Cancer (Urothelial) Pathways Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

Bladder Cancer Pathways (Urothelial)

Bladder Cancer Pathways (Urothelial) Bladder Cancer Pathways (Urothelial) Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op

More information

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong

More information

2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous

2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous Breast Cancer Patients: Begin on page 1, then skip to page 3 Lymphoma Patients: Begin on page 2 1. Newly diagnosed with Breast carcinoma Stage: (includes inflammatory breast and newly diagnosed recurrent

More information

UNDERWRITING GUIDE. Secure Advantage HOSPITAL COVERAGE. The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization

UNDERWRITING GUIDE. Secure Advantage HOSPITAL COVERAGE. The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization UNDERWRITING GUIDE Secure Advantage HOSPITAL COVERAGE The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization TABLE OF CONTENTS Contents Page Secure Advantage Underwriting Guide...2

More information

AD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25

AD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25 A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,

More information

MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS

MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black

More information

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of

More information

EquiCash UNDERWRITING GUIDE. Equitable &You. The Policy That Pays You Cash In The Event You Have To Be Hospitalized HOSPITAL PLAN

EquiCash UNDERWRITING GUIDE. Equitable &You. The Policy That Pays You Cash In The Event You Have To Be Hospitalized HOSPITAL PLAN UNDERWRITING GUIDE EquiCash HOSPITAL PLAN The Policy That Pays You Cash In The Event You Have To Be Hospitalized Rev. 10/13 Equitable &You... Committed To Caring TABLE OF CONTENTS Contents Page EquiCash

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com

Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com Drug & compendia Treatment of Leukemia With each publication, Managed Care Oncology s Drug & Compendia highlights a single medication or a group of medications that could be utilized in the management

More information

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders 1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive

More information

Hazardous Medication List

Hazardous Medication List Hazardous Medication List REDUCING OCCUPATIONAL EXPOSURE TO HAZARDOUS MEDICATION FOR ALL STAFF Table of Contents Hazardous Medication List Key Points... 1 Hazardous Medication List... 2 Special Handling

More information

Haematology, Oncology and Palliative Care Directorate.

Haematology, Oncology and Palliative Care Directorate. Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile

More information

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this

More information

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205

More information

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation. Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant

More information

Part B payment for drugs in Medicare 0

Part B payment for drugs in Medicare 0 Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the

More information

DRUG PROPERTIES YOU NEED TO KNOW

DRUG PROPERTIES YOU NEED TO KNOW Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class

More information

BLOOD AND LYMPH CANCERS

BLOOD AND LYMPH CANCERS BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber

More information

Hazard Meds: Navigating the Warning Beacons

Hazard Meds: Navigating the Warning Beacons Hazard Meds: Navigating the Warning Beacons Disclosures I have nothing to disclose at this time. Mark Twohey, Pharm.D., BCOP Palmetto Health Richland March 24, 2012 Objectives Understand the reasons for

More information

REGULATORY INFORMATION

REGULATORY INFORMATION REGULATORY*INFORMATION/*CANCER*MEDICINES* Summary'of'regulatory'status'of'the'medicines' As#recommended#in#the#EML#Secretariat s#instructions#regarding#applications#for#the#addition#of#new# medicines#

More information

Prior Authorization Proposal: Oncology Agents

Prior Authorization Proposal: Oncology Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Objectives. Principles of Cancer Treatment. Cancer Treatment Modalities. Cancer Treatment Modalities

Objectives. Principles of Cancer Treatment. Cancer Treatment Modalities. Cancer Treatment Modalities Objectives Principles of Cancer Treatment Juanita Madison, RN, MN, AOCN Oncology Clinical Nurse Specialist Seattle Cancer Care Alliance Describe the principles of cancer treatment Surgery Chemotherapy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!! UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have

More information

Medications currently available to treat Multiple Myeloma include: Current Code Price (AWP) Effective Date. Code Price (AWP)

Medications currently available to treat Multiple Myeloma include: Current Code Price (AWP) Effective Date. Code Price (AWP) drug and administration compendia Compendia information developed and maintained by With each publication Managed Care Oncology s Drug & Compendia will highlight a single medication or a group of medications

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Chemotherapy Agents 101

Chemotherapy Agents 101 Chemotherapy Agents 101 Jumana Ashy, Pharm D, BCOP Judith Misas, PharmD Candidate 2018 Jeremy Hutchinson, PharmD Sady Castance, PharmD September 12, 2017 1 Learning Objectives At the end of the presentation

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration

Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration Drug & Administration compendia Treatment of Melanoma With each publication, ManagedCare Oncology s Drug & Administration Compendia highlights a single medication or a group of medications that could be

More information

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.

More information

Part B payment for drugs in Medicare 0

Part B payment for drugs in Medicare 0 Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the

More information

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with Chemotherapy Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK

More information

Chapter 2 Clinical Anticancer Drugs for Cancer Treatment

Chapter 2 Clinical Anticancer Drugs for Cancer Treatment Chapter 2 Clinical Anticancer Drugs for Cancer Treatment Besides cytoreductive surgery and radiotherapy, chemotherapy is the most widely used therapeutic strategy in combating cancer. The high incidence

More information

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,

More information

Supplementary Table 1. Summary of FDA approval data for rare cancer indications from December 1987 to May 2011

Supplementary Table 1. Summary of FDA approval data for rare cancer indications from December 1987 to May 2011 Rare Cancer : Lessons from FDA s by Gaddipati et al. Supplementary Table 1 Summary of FDA approval data for rare cancer indications from December 1987 to May 2011 1. mitoxantrone hydrochloride (NOVANTRONE

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC 1 Conflicts of Interest Damon Hostin Has no real or apparent conflicts

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Figure 1. Characterization of the generated hipsc lines a) Western blot analysis indicating the efficient downregulation of p53 upon knockdown in three hipsc lines (

More information

Cancer drug approvals for paediatric indications (n=43)

Cancer drug approvals for paediatric indications (n=43) Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December

More information

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY

More information

Fundamentals of Pharmacology for Veterinary Technicians Chapter 20

Fundamentals of Pharmacology for Veterinary Technicians Chapter 20 Figure 20-1 Figure 20-2 Figure 20-3A Figure 20-3B Figure 20-4 Table 20-1 Antineoplastic Agents Used for Chemotherapy in Animals Drug Type Drug Category Examples Cell-Cycle Effect CCNS Alkylating agents:

More information

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: Palonosetron Hydrochloride (Aloxi ) 09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Chemotherapy and biotherapy: guidelines and recommendations for practice.

Chemotherapy and biotherapy: guidelines and recommendations for practice. Complete Summary GUIDELINE TITLE Chemotherapy and biotherapy: guidelines and recommendations for practice. BIBLIOGRAPHIC SOURCE(S) Oncology Nursing Society (ONS). Chemotherapy and biotherapy: guidelines

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

Re: Integrated Oncology Management Program with evicore healthcare: Update on codes requiring precertification

Re: Integrated Oncology Management Program with evicore healthcare: Update on codes requiring precertification Ajani Nimmagadda, MD Senior Medical Director , , Re: Integrated Oncology Management Program with evicore

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

Cancer Drugs CANCER DRUGS NEW DRUGS AND INDICATIONS OVER THE PAST TEN YEARS

Cancer Drugs CANCER DRUGS NEW DRUGS AND INDICATIONS OVER THE PAST TEN YEARS Cancer Drugs NEW DRUGS AND INDICATIONS OVER THE PAST TEN YEARS by KONG KHOO, ROSEMARY COLUCCI, DANIEL GILLESPIE, JAMES D. GOWING, PIERRE MAJOR, JOSEPH RAGAZ, DAVID SALTMAN, COLLEEN SAVAGE Development of

More information

Working Formulary January 2013 Oncology Chemotherapy Regimens

Working Formulary January 2013 Oncology Chemotherapy Regimens Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy

More information

3/8/2018. Treatment Modalities. Study Resources. Study Resources. New 2018 OCN Test Blueprint

3/8/2018. Treatment Modalities. Study Resources. Study Resources. New 2018 OCN Test Blueprint New 2018 OCN Test Blueprint Treatment Modalities Nancy Thompson, MSN, RN, AOCNS Director of Quality & Clinical Practice Swedish Cancer Institute March 17, 2018 Content Area Sub-Content Areas 2018 Test%

More information

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed

More information

Lung Cancer Patient Survey

Lung Cancer Patient Survey Lung Cancer Patient Survey Registered User Who is filling out the lung cancer questionnaire? The patient (person diagnosed with lung cancer) Spouse Parent Legal guardian Other relative Other non-relative

More information

DRUG PROPERTIES YOU NEED TO KNOW

DRUG PROPERTIES YOU NEED TO KNOW jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 8 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class b. resistance 2. Pharmacokinetics 3. Therapeutic uses 4. Major side effects/toxicities

More information

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations

More information

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Adjuvant Systemic Therapy in Early Stage Breast Cancer Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington

More information

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,

More information

Disclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015

Disclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015 Disclosure Oncologic Emergencies and Acute Supportive Care of the Critically Ill Oncology Patient By: Kimberly Regis, Pharm.D. Broward Health Medical Center Pharmacy Resident 2014-2015 I do not have a

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and 35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting

More information

The AngCN Antiemetic Guidelines

The AngCN Antiemetic Guidelines The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction

More information

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information